108 reports of this reaction
3.1% of all FELBAMATE reports
#5 most reported adverse reaction
SOMNOLENCE is the #5 most commonly reported adverse reaction for FELBAMATE, manufactured by Viatris Specialty LLC. There are 108 FDA adverse event reports linking FELBAMATE to SOMNOLENCE. This represents approximately 3.1% of all 3,510 adverse event reports for this drug.
Patients taking FELBAMATE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is moderately reported among FELBAMATE users, representing a notable but not dominant share of adverse events.
In addition to somnolence, the following adverse reactions have been reported for FELBAMATE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 108 FDA reports for FELBAMATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 3.1% of all adverse event reports for FELBAMATE, making it a notable side effect.
If you experience somnolence while taking FELBAMATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.